Core Insights - Maase Inc. has appointed Mr. Jingkai Li as the new chairman of the board, succeeding Ms. Hong Suong Nguyen, effective November 28, 2025 [1][2][3] Company Overview - Maase Inc. was founded in 2010 and has evolved from being known as Highest Performances Holdings Inc. and Puyi Inc. to a provider of intelligent technology-driven family and enterprise services [4] - The company's mission focuses on enhancing the quality of life for families globally through technological intelligence and capital investments, targeting high-quality enterprises with global potential [4] Leadership Background - Mr. Jingkai Li holds an executive master's degree in business administration from Macau University of Science and Technology and has over a decade of experience in the green industry [2] - He previously led Guangxi Qinyuan Environmental Protection Co., Ltd., where he built a technology-driven environmental protection industrial group, gaining expertise in operational management and industrial integration [2] - Mr. Li's experience includes strategic investments in new energy and smart technology sectors, positioning him as an ideal leader for Maase's growth [2] Strategic Vision - Mr. Li expressed his commitment to leveraging his experience in the green industry and strategic investment to foster innovation across Maase's business units [3] - The company has shown significant potential in areas such as smart car wash, energy storage batteries, and wellness businesses, which Mr. Li aims to capitalize on [3]

Core Viewpoint - Rakovina Therapeutics Inc. has announced the extension of the maturity date for its 12.0% convertible debentures from November 29, 2025, to January 28, 2026, following consent from debentureholders representing at least 66 2/3% of the outstanding principal [1][2] Group 1: Convertible Debentures - The total principal amount of the convertible debentures is $1,454,000.00, and the interest rate will remain at 12.0% during the extension period [1][2] - The extension is subject to approval from the TSX Venture Exchange [2] Group 2: Related Party Disclosure - Certain directors of the company own approximately $100,000 principal amount of the convertible debentures, representing about 6.9% of the outstanding principal [3] - The participation of these directors in the extension is classified as a "related party transaction" under applicable regulations, and the company has relied on exemptions from formal valuation and minority shareholder approval requirements [3] Group 3: Warrant Incentive Program - The company's early exercise warrant incentive program expired on September 2, 2025, with no warrants being exercised [4] Group 4: Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered technologies for targeting DNA-damage response [5][6] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [6]

Core Points - Algernon Health Inc. has closed the second tranche of its non-brokered private placement, raising gross proceeds of CAD $210,000 from the sale of 3,000,000 units at an issue price of CAD $0.07 per unit [2][3] - The funds raised will be utilized to advance the company's Alzheimer's Disease program, including the opening of its first U.S. Alzheimer's Disease clinic, as well as for general administrative expenses and working capital [3] - The securities issued are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with Canadian securities legislation [4] Company Overview - Algernon Health is a Canadian healthcare company focused on providing brain-optimized PET scanning services for early-stage detection of Alzheimer's Disease and other neurological conditions [6] - The company has established a private subsidiary, Algernon USA LLC, to oversee its U.S. neuroimaging operations [6]

Core Insights - PharmaCorp RX Inc. reported strong operational momentum and financial performance for Q3 2025, driven by increased revenues, improved margins, and better operating efficiencies [2][4] - The company completed acquisitions of three pharmacies, enhancing its national presence and supporting its coast-to-coast ambitions [2][6][7] - Same-store sales increased by 9.4% year-over-year, and total prescription volumes rose by 7.2% compared to Q3 2024, indicating sustained growth in patient engagement [9] Financial Highlights - The reported net loss for the quarter reflects investments in corporate infrastructure and one-time legal fees related to obtaining a credit facility [5][9] - The company raised approximately C$23.0 million through a bought deal public offering, selling 54,855,000 units at C$0.42 per unit [8] - Solid pharmacy-level contribution margins and a disciplined approach to EBITDA multiples across acquisitions support PharmaCorp's long-term growth model [9] Operational Update - Key investments were made in systems, personnel, and integration processes to facilitate scalable national growth [5] - The company operates seven PharmaChoice Canada bannered pharmacies and aims to acquire more pharmacies, rebranding them under the PharmaChoice Canada platform [12]

Core Points - Spirit Blockchain Capital Inc. has filed its interim financial statements for the three and nine months ended September 30, 2025, in compliance with Canadian Securities Exchange requirements [1] - Lewis Bateman has been appointed as Interim Chief Financial Officer following the departure of Inder Saini [2] - Spirit Blockchain Capital focuses on developing blockchain-based financial infrastructure, including tokenization platforms and digital-asset services, aiming to generate recurring revenue [3]

Executive Transition - PharmaCorp RX Inc. announced the appointment of Paul Dale as President and Chief Operating Officer effective December 1, 2025, as Calvin LeRoux transitions to a one-year role as Strategic Advisor to the CEO [1][2] - Paul Dale has been with PharmaCorp since its inception as Chief Operating Officer and will now take on broader leadership responsibilities to support the company's national expansion strategy [2] - Calvin LeRoux will assist in the transition and continue to provide guidance on strategic initiatives and matters related to PharmaChoice Canada in his new advisory role [2] New Appointment - Sophia Sigler will join PharmaCorp as Director of Business Development effective December 1, 2025, leading business development initiatives, including sourcing acquisition opportunities and managing the transaction pipeline [2] Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [3] - The company operates seven PharmaChoice Canada bannered pharmacies and aims to acquire both bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform [3]

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce its unaudited quarterly results as at and for the three months September 30, 2025. As at September 30, 2025, the Company had cash, investments and digital assets of $26.5 million. As at September 30, 2025, net asset value per ...

Vancouver, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- NEW EARTH RESOURCES CORP. (CSE: EATH) ("New Earth" or the "Company") is pleased to announce that it has issued 1,250,000 Class A common shares of the Company (each, a “Share”) under its recently announced option agreement (the “Agreement”) dated as of November 19, 2025 with Northex Capital Partners Inc. (“Northex”) under which the Company has the option to acquire the Red Wine Rare Earth Project (the “Project”). The Project is comprised of 2 non ...

Core Insights - KINGSONG has launched the F18, the world's first modular electric unicycle featuring a 4-point suspension system, catering to the growing demand for high-performance personal mobility [1][20][23] Product Features - The F18's modular design allows users to easily detach and swap parts, enhancing personalization and functionality, with a quick-release motor that can be removed in under two minutes [5][6] - It incorporates a magnesium alloy frame that is 28% lighter than aluminum, providing a 52% increase in yield strength and superior damping capabilities [6] - The four-point suspension system offers 25 levels of damping adjustments, ensuring comfort and stability across various terrains [7][8] Performance Specifications - The F18 is powered by a 5000W motor, achieving speeds over 120 km/h and a maximum climb angle of 45° [14] - It features a 2664Wh Samsung 50S battery, providing an approximate range of 150 km and supporting fast charging in about 1 hour [11][15] Safety and Technology - The device includes a Smart Battery Management System (BMS) for enhanced stability and safety, protecting against over-charging and temperature fluctuations [10][15] - Safety features include integration with the Apple Find My network for device tracking and a comprehensive lighting system for nighttime visibility [16] Company Background - Founded in 2012, KINGSONG has established itself as a leader in smart personal mobility, operating from an 18,000 sqm facility with over 200 skilled employees [18][25] - The company holds more than 100 patents and has received multiple international design awards, emphasizing its commitment to innovation and quality [19][26] Market Positioning - The F18 reflects KINGSONG's understanding of market trends, focusing on modularity, high performance, and safety, which are essential for today's consumers [20][23] - The company offers a range of products, including electric unicycles, e-scooters, and e-bikes, catering to diverse mobility needs [27][28]

EAST HANOVER, N.J., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Mondelēz Global LLC announced today a voluntary recall of 70 cases of RITZ Peanut Butter Cracker Sandwiches and sold in the following U.S. states: New York, New Jersey, Pennsylvania, Georgia, Arkansas, Missouri, Oklahoma, and Alabama. This recall is limited to 1 SKU and 2 Code Dates previously recalled in July. This action is not an expansion of that prior recall and is being conducted out of an abundance of caution. The affected cartons include individu ...